
Fan Luo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2498169/publications.pdf Version: 2024-02-01



FANLUO

#	Article	IF	CITATIONS
1	A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma. Oncologist, 2022, 27, e453-e462.	3.7	9
2	CirclTGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. , 2022, 10, e004029.		44
3	Clinical Significance of Kinetics of Low-Density Lipoprotein Cholesterol and Its Prognostic Value in Limited Stage Small Cell Lung Cancer Patients. Cancer Control, 2021, 28, 107327482110282.	1.8	5
4	Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China. Journal of Hematology and Oncology, 2021, 14, 124.	17.0	12
5	Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. Cancer Cell International, 2021, 21, 458.	4.1	7
6	Emerging immunological strategies: recent advances and future directions. Frontiers of Medicine, 2021, 15, 805-828.	3.4	5
7	Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e2015748.	5.9	36
8	Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a firstâ€line treatment for advanced EGFRâ€mutant nonâ€small cell lung cancer. Clinical and Translational Medicine, 2020, 10, e33.	4.0	13
9	Prognostic value of serum highâ€density lipoprotein cholesterol elevation in nonsmall cell lung cancer patients receiving radical surgery. Clinical and Translational Medicine, 2020, 10, e94.	4.0	3
10	Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer. Annals of Translational Medicine, 2020, 8, 1589-1589.	1.7	1
11	Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. , 2019, 7, 245.		66
12	Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989165.	3.2	10
13	Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. Annals of Translational Medicine, 2019, 7, 452-452.	1.7	9
14	Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution. Annals of Translational Medicine, 2019, 7, 253-253.	1.7	1
15	Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. Oncologist, 2018, 23, 603-616.	3.7	17
16	Predictive Value of High Preoperative Serum Total Protein and Elevated Hematocrit in Patients with Non-Small-Cell Lung Cancer after Radical Resection. Nutrition and Cancer, 0, , 1-13.	2.0	1